MarketInOut Stock Screener Log In | Sign Up
 

Altimmune Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/23/2026 16:00
Altimmune Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization632.18 mln
Float194 mln
Earnings Date11/10/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

16.79
Highly suspicious

Relative Strength

22 / 100
Significantly lagging

Debt / Equity

0.08
Debt-free

Pre-Tax Margin

-296,000%
Severely loss-making

ROE

-34.49
Deeply negative

Business Description

Altimmune is a medical research company working to bring new treatments to patients suffering from serious liver conditions. Its main drug in development, pemvidutide, targets two key biological pathways at once and is currently being tested in late-stage clinical trials for liver disease linked to metabolic dysfunction as well as alcohol-related conditions. Founded in 1997 and based in Gaithersburg, Maryland, the company is focused on advancing this treatment toward potential approval.

Key Fundamentals

EPS-0.76
ROE-34.49
RPS0.00
ROIC-250
ROA-29.57
Interest Cover-28.34
EBITDA, mln-88.12
EV / EBITDA-3.62
EV / EBIT-3.61
Revenue, mln0.03
EV / Revenue10,277

Quote Details

Last 3.19
Change -0.22 (-6.45%)
Open 3.42
Volume 4,512,775
Turnover 14,395,753
Average Volume 3,822,610

Financial Ratios

Pre-Tax Profit Margin-296,000
Leverage Ratio1.11
Current Ratio26.78
Price / Book1.28
Price / Tangible Book1.28
Debt / Equity0.08
Price / Sales20,388
PEG Ratio32.62

Financial Strength

Altman Z-Score5.23
Piotroski F-Score 4 / 9
Beneish M-Score16.79
Short Ratio11.28
Short % of Float25.59

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.54% 26 / 100   
1 Month 2.57% 79 / 100   
2 Months 21.76% 91 / 100   
6 Months -1.54% 34 / 100   
1 Year -19.44% 28 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us